36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
Randomized controlled trial published in Hypertension research : official journal of the Japanese Society of Hypertension (2024)
Abstract
Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial.
Por qué esto importa para la hirudoterapia
Este análisis comunica los datos de seguimiento a 36 meses del ensayo RADIANCE-HTN TRIO sobre denervación renal endovascular por ultrasonidos (uRDN) frente a procedimiento simulado para la hipertensión resistente. Entre los 49 pacientes con uRDN que completaron el seguimiento, la presión arterial en consulta disminuyó significativamente (–14,5/–9,0 mmHg desde el cribado, p<0,001) sin problemas de seguridad. Este artículo no tiene conexión con la hirudoterapia, la terapia con sanguijuelas o el secretoma de la sanguijuela. No se mencionan sanguijuelas ni moléculas derivadas de sanguijuela. Si bien la hirudoterapia tiene asociaciones históricas con la sangría para afecciones cardiovasculares, este estudio no aporta datos relevantes para ese contexto.
Citación
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
Bloch MJ et al. · Hypertension research : official journal of the Japanese Society of Hypertension, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026